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Abstract
Pseudomonas aeruginosa, a Gram-negative pathogen, causes life-threatening infections. 
Lung injury and the development of sepsis depend largely on expression of the virulence 
genes associated with the type III secretion system of this bacterium. The type III secre-
tion system functions as a molecular syringe to deliver type III secretory toxins directly 
into the cytosol of eukaryotic cells and also acts to inhibit innate immune mechanisms, 
thereby preventing bacterial clearance. Antibodies against PcrV, the cap structure in the 
translocational needle of type III secretory apparatus of P. aeruginosa, block toxin trans-
location of the type III secretion system. We have been investigating the therapeutic use 
of a recombinant anti-PcrV single-chain antibody. In this chapter, as a preliminary step 
toward an antibody-based immunotherapy against bacterial infections, we summarize 
our experience of constructing a recombinant single-chain antibody (called scFv166), in 
which the heavy (V
H
) and light chain (V
L
) variable regions of the anti-PcrV monoclonal 
IgG are joined by a flexible peptide linker. The practical methodologies used to make 
recombinant scFv166 against a bacterial protein component are described in detail.
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1. Introduction
Bacterial infections still frequently cause life-threatening diseases in humans. New patho-
gens have emerged, old pathogens have reemerged, and the prevalence of multidrug resis-
tant microorganisms has increased despite the introduction of various new antibiotics since 
antibacterial agents were first developed in the early twentieth century. The difficulties 
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associated with treating infections in immunocompromised patients have increased the 
need for new adjunctive immunotherapies. During the last 20 years, major advances in the 
techniques used to generate human antibodies and humanize murine monoclonal antibod-
ies have seen antibody-based therapies to arrive as potential candidates for adjuvant thera-
pies for infectious diseases. However, today, antibody therapy for bacterial infections is 
still indicated in relatively few situations, although more attention should be focused on it 
because of the increased levels of bacterial drug resistance and higher numbers of immuno-
compromised patients.
We have been investigating the therapeutic use of recombinant antibodies against the Gram-
negative pathogen, P. aeruginosa. P. aeruginosa is an opportunistic pathogen responsible for a 
variety of acute infections in immunocompromised patients, and chronic infections in those 
with cystic fibrosis [1, 2]. P. aeruginosa is also highly resistant to various antibiotics and causes 
nosocomial pneumonia with an associated high mortality rate despite aggressive treatment 
with antimicrobial drugs [3, 4]. We have been studying the pathogenesis of acute infections 
caused by P. aeruginosa to identify a therapeutic target in this pathogen, and have reported 
that its ability to cause epithelial injury, to disseminate into the circulation, and to avoid host 
innate immune responses is highly associated with its type III secretion system (TTSS) [5–9]. 
The TTSS of Gram-negative bacteria mediates the translocation of toxins from the bacterial 
cytoplasm directly into the cytosol of host eukaryotic cells [10, 11]. Once inside the eukary-
otic cell, these translocated bacterial toxins interfere with signal transduction. TTSSs with 
homology to P. aeruginosa have been described in most Gram-negative bacterial pathogens 
(e.g., Yersinia, Shigella, Salmonella, and Escherichia coli), and all of them are associated with 
pathogenicity [12].
Here, as a preliminary step toward antibody-based immunotherapy against bacterial infec-
tions, we summarize our trial to block the TTSS-associated virulence of P. aeruginosa using 
recombinant antibody technologies. Especially, cloning of the variable domains of the light 
and heavy chain from a hybridoma cell and assembling the cloned V
H
 and V
L
 domains 
to recombinant single-chain antibody (scFv) to confirm the binding to the target antigen 
are required steps to humanize murine antibody. In addition to a brief explanation of the 
P. aeruginosa TTSS and the concept of a virulence blockade, the advantage of a recombi-
nant single-chain antibody (scFv), the detailed methods to clone the variable domains from 
hybridoma cells and construction of scFv166, in which the heavy (V
H
) and light chain (V
L
) 
variable regions of the anti-PcrV monoclonal IgG molecule are joined by a flexible peptide 
linker, will be described.
2. Antibody-based blockade of P. aeruginosa type III secretion
P. aeruginosa translocates its virulent TTS toxins (ExoS, ExoT, ExoU, and ExoY) directly into 
eukaryotic cells to disrupt their normal cellular processes [12, 13]. The translocation of ExoS 
and ExoT proteins, which both have ADP-ribosyltransferase and GTPase activities,  inhibits 
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the phagocytic activities of macrophages [14, 15]. The translocation of ExoU, which has 
patatin-like phospholipase A
2
 activity, is correlated with acute cytotoxicity in vitro and lung 
damage, sepsis, and mortality in animal models [7, 16–20]. The translocation of ExoY, which 
possesses adenylate cyclase activity, causes an increase of cytosolic cyclic AMP in eukaryotic 
cells and affects cell morphology [21]. In our past clinical study, we discovered an association 
between patients infected with TTSS-expressing P. aeruginosa strains and mortality [22], and 
other reports from various countries have supported the association of TTSS with severe clini-
cal outcomes in patients infected with this bacterium [19].
In the TTSS, the translocated toxins are not exposed extracellularly and evade direct recog-
nition by the host immune system. Therefore, targeting the protein factors involved in the 
“secretion” or the “translocation” process of the TTSS seems a rational approach for blocking 
TTS virulence. To target the TTSS of P. aeruginosa, we have been developing neutralizing anti-
bodies capable of blocking the translocation process of the TTSS [23]. An obvious candidate 
for a protective antigen was PcrV as it shares relatively high homology with the protective 
antigen from Yersinia sp., LcrV [6, 24-33]. Using genetic analyses, we demonstrated that PopD 
and PcrV were required for the delivery of P. aeruginosa-encoded TTS toxins [23]. In addi-
tion, recombinant TTS proteins, such as ExoU, PcrV, and PopD, were produced, purified, and 
tested for their protective capacities in a model of acute lung infection in mice. Only PcrV 
was protective in these experiments. Antibodies to PcrV protected against type III intoxica-
tion as shown by the inhibition of translocation of ExoY and by the inhibition of macrophage 
cytotoxicity mediated by ExoU. Passive protection with anti-PcrV reduced the inflammatory 
response, minimized bacteremia, and prevented septic shock [23]. Moreover, the protective 
capacity of the antibody was Fc-independent because F(ab’)
2
 fragments of polyclonal anti-
PcrV were also effective [34–36].
In our previous study, the Mab166 murine monoclonal antibody, which has neutralizing 
effects on virulence of the P. aeruginosa TTSS, was developed [35]. Also, the Fab fragments 
of the Mab166 had comparable therapeutic effects to the whole IgG of Mab166 in preventing 
P. aeruginosa-induced acute lung injury, and the Fc-dependent opsonization of the bacteria 
does not seem critical for the efficacy of the Mab166 [36]. These results implicate that the 
blockade of type III secretion-associated virulence can be attained by the effective Fab frag-
ment of IgG molecules. Because the Fc-portion of IgG may induce unfavorable inflamma-
tory responses such as complement fixation, activation of macrophages, the administration of 
the whole IgG may cause some inflammatory side effects. If the Fab fragment had the same 
therapeutic potency as the whole IgG, the therapeutic administration of either Fab fragments 
or scFv might overcome the disadvantages of the intratracheal administration of whole IgG. 
Therefore, the E. coli-derived recombinant scFv against PcrV is attractive to be an effective 
therapeutic agent against P. aeruginosa pneumonia.
In the next chapter, we describe the methods used to clone the variable antibody domains V
H
 
and V
L
 from hybridoma cells and assembly of a single-chain antibody as an E. coli-derived 
recombinant protein. Previously, the engineered recombinant Fab fragment against PcrV was 
humanized to allow it to be considered for adjunctive therapy in patients [37–39].
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3. Methods for construction of a single-chain antibody
3.1. Cloning the variable V
H
 and V
L
 domains from hybridoma cells
3.1.1. Poly A+ RNA extraction
The anti-PcrV IgG Mab166 hybridoma cell line [35] was cultured in a standard culture 
medium. After the cells had reached confluence in a 75 cm2 flask, they were harvested by cen-
trifugation at 600 rpm for 5 min. The cell pellet was homogenized in 2 mL of TRIzol™ reagent 
(Thermo Fisher Scientific, Waltham, MA, USA), and total RNA extracted after chloroform 
fractionation, isopropanol precipitation, and washing with 70% ethanol. Poly A+ RNA was 
extracted with an oligotex mRNA spin-column (Qiagen, Valencia, CA).
3.1.2. RNA oligo-capping
To clone the variable V
H
 and V
L
 domains from the total RNA, the oligo-capping method 
reported by Maruyama and Sugano [40] using a GeneRacer™ kit (Thermo Fisher Scientific) 
was used. mRNA (250 ng) was incubated with calf intestinal phosphatase at 50 °C for 1 h to 
dephosphorylate non-mRNA or truncated mRNA species. After the reaction, phenol-chlo-
roform extraction and ethanol precipitation were performed, and the dephosphorylated 
RNA was incubated with tobacco acid pyrophosphatase at 37°C for 1 h to remove the 5’-cap 
structure from the full-length mRNA. After phenol-chloroform extraction and ethanol pre-
cipitation, the synthetic RNA oligo (GeneRacer™ RNA Oligo, Thermo Fisher Scientific) was 
ligated to the decapped RNA with T4 RNA ligase at 37°C for 1 h. After phenol-chloroform 
extraction and ethanol precipitation, the RNA was suspended in diethylpyrocarbonate-
treated water.
3.1.3. Reverse transcription of mRNA
The RNA-oligo ligated, full-length mRNA was reverse transcribed using a 54 base-pair 
primer containing an 18 nucleotide dT tail (GeneRacer™ Oligo-dT, Thermo Fisher Scientific) 
and avian myeloblastosis virus reverse transcriptase at 42°C for 1 h. After the reaction, the 
sample was diluted four times with sterile water.
3.1.4. Construction of a single-chain antibody gene
The cDNAs encoding V regions of the heavy and light (kappa) chains were PCR-amplified 
using a set of primers (V
H
 forward: 5'-TGA GGA GAC GGT GAC TGA GGT TCC-3', V
H
 
reverse : 5'-CAG GTG CAG CTG AAG CAG TCA GG-3', V
k2
 forward: 5'-CCG TTT TAT TTC 
CAG CTT GGT CCC-3', V
k
 reverse : 5'-GAC ATC CAG ATG ACT CAG TCT CCA-3'). PCRs 
were run over 30 cycles (94°C for 30 sec, 60°C for 40 sec, and 72°C for 40 sec). V
H
 and V
L
 frag-
ment-amplified PCR products were purified separately by agarose gel electrophoresis. The 
PCR products derived from the murine immunoglobulin V
H
 and V
L
 domain of Mab166 were 
subcloned into a pCR2.1 vector (TOPO cloningTM, Thermo Fisher Scientific) and submitted to 
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a DNA sequencing service for DNA sequence acquisition and analysis. Sequencing of the 
immunoglobulin variable genes for Mab166 was analyzed by The International imMunoGe-
neTics Database IMGT (http://www.imgt.org).
The purified V
H
 and V
L
 cDNAs were each assembled into a single gene using a DNA linker frag-
ment-encoding a glycine-serine (Gly
4
Ser)
3
 linker peptide, thereby connecting the two cDNAs in 
the correct reading frame. Assembly PCR was run with a set of primers to multiply V
H
-linker-V
L
. 
The assembled fragment was amplified using two oligonucleotide primers with either an NcoI 
or XbaI restriction enzyme site at the 5’ end to facilitate cloning of the PCR product into a pBAD/
gene III plasmid (Thermo Fisher Scientific) (Figure 1). The ligation mixture was used to transform 
E. coli TOP10 cells (Thermo Fisher Scientific), and subsequently to transform E. coli LMG194.
3.2. Expression and purification of recombinant single-chain antibody fragments
3.2.1. Expression and purification of scFv166
scFv166 protein expression was induced in the E. coli plasmid-harboring transformants by 
adding L-arabinose to a final concentration of 0.004%. After 24 h culture at 26°C with agitation 
at 200 rpm, the cells were collected by centrifugation at 5000× g for 20 min and then incubated 
in phosphate-buffered saline (PBS) with 1 mM ethylenediaminetetraacetic acid for 10 min 
on ice to obtain the periplasmic fraction. The osmotically shocked lysate was centrifuged at 
15,000× g for 20 min, passed through a 0.4-μm-pore-size filter and dialyzed overnight against 
Figure 1. Expression vector pBAD/gIII::m166-HLL. The assembled scFv166 gene was subcloned into the pBAD/Gene III 
E. coli expression vector, downstream of, and in frame with, the gene III secretory leader sequence using NcoI and XbaI 
restriction sites.
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lysis buffer (50 mM NaH
2
PO
4
, 300 mM NaCl, 10 mM imidazole, 0.05% Tween 20, pH 8.0). The 
lysate was mixed with nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) for 30 min at 4°C with 
gentle shaking. After the Ni-NTA agarose was collected by centrifugation (4000× g), it was 
resuspended in lysis buffer and packed onto the chromatography column.
The column was washed twice with washing buffer (50 mM NaH
2
PO
4
, 300 mM NaCl, 20 mM 
imidazole, 0.05% Tween 20, pH 8.0), and the bound scFv166 antibodies were eluted with elu-
tion buffer (50 mM NaH
2
PO
4
, 300 mM NaCl, 250 mM imidazole, 0.05% Tween 20, pH 8.0). 
The eluate was dialyzed against PBS overnight and applied to an endotoxin removal column 
(Detoxi-Gel, Thermo Fisher Scientific) to get rid of the contaminating endotoxin. The purified 
antibodies were stored at −80°C until use.
In this study, we assembled the variable regions of the heavy and light chains of the anti-PcrV 
monoclonal IgG together with a glycine-serine linker in a single-chain antibody format. First, 
we assembled scFv166 in two different formats: one with V
H
-linker-V
k
 positioned between 
the two variable segments (Figure 2), the other with V
k
-linker-V
H
 positioned between two 
variable segments. The assembled scFv166 gene was subcloned into the E. coli pBAD/gene III 
expression vector, downstream of, and in frame with, the gene III secretory leader sequence. 
Expression of recombinant scFv166 was induced in E. coli by arabinose, after which it was 
purified via its C-terminal hexahistidine tag using Ni-NTA resin and conventional affinity 
column techniques. However, scFv-V
L
-linker-V
H
 was highly insoluble, despite the expressed 
protein being detected in the whole lysates from E. coli cells after arabinose induction. Because 
scFv166 with its associated V
H
-linker-V
L
 fragment was easier to purify as a soluble protein, 
we decided to focus on purifying it in that format. The purified scFv166 recognized the PcrV 
antigen in ELISAs and western immunoblots, as described in the next section.
3.3. Protein gels and immunoblot analyses
The purity of scFv166 was evaluated using sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Coomassie Blue staining (Figure 3). Briefly, samples of E. coli 
lysate were loaded onto a 4–15% Tris-HCl gel (BioRad Laboratories Inc., Hercules, CA, USA) 
and, after electrophoresis, the gel was stained with Coomassie Blue. For the immunoblot anal-
ysis, after SDS-PAGE, the protein was transferred to a nitrocellulose membrane and immu-
nostained with a horseradish peroxidase-conjugated anti-c-myc IgG antibody, after which 
the blot was developed with a chemiluminescent substrate (ECL, GE Healthcare Bioscience, 
Piscataway, NJ). Immunoblots of scFv166 and precipitated P. aeruginosa proteins were also 
performed (Figure 4). P. aeruginosa PA103 was cultured in tryptic soy broth deferrated with 
nitrilotriacetic acid for 24 h at 31°C and, after centrifugation at 5000× g for 20 min, the super-
natant was harvested. Saturated ammonium sulfate solution was added (final concentration, 
55%), and the solution was incubated on ice for 1 h, and then centrifuged (20,000 × g, 30 min). 
The precipitated proteins were resuspended in 100 μL of PBS. After adding 100 μL of SDS-
PAGE sample buffer and boiling for 5 min, the sample was analyzed by SDS-PAGE. After 
electrophoresis, the proteins were blotted onto a nitrocellulose membrane, and then immu-
nostained with scFv166 and a horseradish peroxidase-conjugated anti-c-myc IgG secondary 
antibody, and the blot was developed with ECL.
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3.4. Affinity determination of scFv166
The affinity of scFv166 for its cognate antigen was determined by competition ELISA, and the 
result was compared with that of the hybridoma-derived parental Mab166, as described 
previously [41], Figure 5. Briefly, in the first step, the total antibody concentration range in 
which the absorbance correlates proportionately with the free antibody concentration was 
Figure 2. scFv166 nucleotide sequence. After the gene III signal sequence (18 aa) and the short joint region (6 aa), the V
H
 
region (123 aa) is followed by the glycine-serine linker (15 aa), the V
L
 region (108 aa), a cMyc-tag, and a hexahistidine-tag.
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measured by indirect ELISA with the PcrV antigen coated at 1 μg/mL. In the second step, 
K
d
, the dissociation constant, was measured using binding equilibrium studies (competition 
ELISA) to determine the concentration that gives 50% inhibition of maximum binding.
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Figure 3. Expression and purification of scFv166. E. coli lysates were loaded onto a 4–15% gradient Tris-HCl gel and, 
after electrophoresis, the gel was stained with Coomassie Blue. For the immunoblot analysis, after polyacrylamide 
gel electrophoresis, the protein was blotted onto a nitrocellulose membrane and immunostained with a horseradish 
peroxidase-conjugated anti-c-Myc IgG antibody, and the blot was developed with a chemiluminescent substrate. The 
secreted scFv166 (298 amino acids) was detected as a 29.7 kD-band in the elute-1 and elute-2, designated by arrows. 
Soluble fraction: the osmotically shocked lysate; elute: the eluted solution from an Ni-NTA agarose column; soluble 
fraction after elution: the solution passed through an Ni-NTA agarose column (two sets of the lysate and the column 
elute were analyzed and labeled “−1” and “−2”, respectively).
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Figure 4. Immunoblot of P. aeruginosa proteins reacted with scFv166. Precipitated P. aeruginosa PA103 proteins were 
resuspended in 100 μL of PBS. After adding 100 μL of SDS-PAGE sample buffer and boiling for 5 min, the proteins in the 
sample were separated by SDS-PAGE with E. coli-derived recombinant PcrV (rPcrV) as a reference. After electrophoresis, 
the proteins were transferred to a nitrocellulose membrane, and immunostained with scFv166 and a horseradish 
peroxidase-conjugated secondary anti-c-Myc IgG antibody and the blot was developed with a chemiluminescent substrate. 
The bindings of scFv166 to both native PA103 PcrV (294 amino aicds, 32.4 kD) and recombinant PcrV (rPcrV, 306 amino 
acids, 33.8 kD) were detected as shown in arrows.
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4. Results
4.1. Aminoacid sequence of V
H
, V
L
 of scFv166
The sequence of the Mab166 heavy chain region is shown in Figure 2. The DNA sequence 
of the 5’-untranslational region and a V-region segment in the heavy chain-containing com-
plementarity determining regions (CDRs) 1 and 2 is identical (except two amino acids in 
the frame 3 region) to germline Musmus IGHV2S2 (IGHV subgroup 2, V
H
#101, Accession 
#J00502). The V-region sequence also shows the same level of homology as that reported 
for pseudogene, IGHV2S5 (Accession #M21165). Transcription starts 24 nucleotides down-
stream of the TATA box of germline IGHV2S2. Nucleotides differ from the germline 
sequence at 10 positions, and these cause the following amino acid changes: position #61 
in CDR2 S->D, #87 in FR3 V->L, #95 Q->R, and #96 S->A, #97 N->T. The first 15 nucleotides 
in the D-region encode the first 5 unique amino acids in CDR3, and the region consists 
of 16 amino acids in total. The J-region DNA sequence is identical to the IGHJ4 germ-
line sequence (Accession #V00770). The unique CDR3 sequence includes the Arg-Gly-Asp 
(RGD) sequence, which functions as a recognition sequence for adhesion receptors in many 
adhesive proteins including fibrinogen, fibronectin, von Willebrand factor, and vitronectin.
The nucleotide sequence of the variable region of the kappa light chain, along with its predicted 
amino acid sequence, is shown in Figure 2. The CDRs are underlined, and the amino acids are 
numbered according to a convention. This kappa variable chain is a class II mouse kappa vari-
able region. Although its sequence is not identical to any germline variable regions present 
in the data bank (The International ImMunoGeneTics Database IMGT), the DNA sequence 
of the 5’-untranslational region, and V-region of the kappa light chain shows the highest 
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Figure 5. Binding affinities of Mab166 and scFv166 in competition ELISA. Binding affinities (K
d
) of Mab166 and scFv166 
to immobilized PcrV were evaluated in a competition ELISA.
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homology to germline Musumus IGKV12-41*01F (IGKV subgroup 12, Accession #AJ235953). 
Transcription starts from nine nucleotides downstream of the TATA box. Nucleotides differ 
from the germline sequence at four positions (+#192, C->A), (+#218, A->C), (+#250, A->T, +#251, 
A->C), and they cause amino acid changes at the following positions: #30 in CDR1 H->Q, #45 
in FR2 K->T, and #56 in CDR2 N->S. The DNA sequence in the J-region is identical to germline 
IGKJ2 (Accession #V00777).
4.2. Evaluation of the expressed scFv166
Immunoblot to the anti-cMyc tag visualized the secreted scFv166 (298 amino acids) as a pre-
dicted 29.8 kD-band in the eluted solution from Ni-NTA agarose as shown in Figure 3. The 
bindings of scFv166 to both native PA103 PcrV (294 amino acids, 32.4 kD) and recombinant 
PcrV(rPcrV, 306 amino acids, 33.8 kD) were confirmed as shown in Figure 4. The binding 
affinity of Mab166 was 1 × 10−8 M, while that of scFv166 was 5 × 10−6 M (Figure 5).
4.3. Humanization and affinity maturation
The next step, for human use, after testing the binding affinity of scFv166 to a target mol-
ecule, together with the affinity maturation steps, is the elimination of the human-specific 
antigenic mouse amino acid sequence. In fact, Mab166 has already been humanized by 
antibody affinity engineering by serial epitope-guided complementarity replacement 
(SECR) which is a licensed humanization/affinity maturation technique of KaloBios 
Pharmaceutical Inc (Brisbane, California, USA) [33, 37] (Figure 6). In brief, SECR provides 
for a method for obtaining human idiologs for any nonhuman antibody to any target by 
epitope-guided replacement of variable regions using competitive cell-based methods in 
which the competitor can be either the reference antibody or a ligand that binds to the 
same epitope on the target as the reference antibody [37]. Fab 1A8 of humanized Mab166 
by SECR bound to PcrV with approximately a twofold-higher affinity than the original 
murine Mab166 Fab [37]. Therefore, a further modification of scFv166 can be done by 
referring to the existing information available for the modified amino acid sequences in 
Fab 1A8 [33].
light chain κ
 (X D S/G)
heavy chain IgG2b CDR3 
CDR3 
FR4  FGGGTKLTVLR
(X D M/F, Z D I/S/Q)
murine (Mab166)humanized (1A8)
murine (Mab166)humanized (1A8)
murine (Mab166)humanized (1A8)
NRGDIYYDFTYAMDYNRGDIYYDFTYAXDZ
QHFWSTPYTQQFWXTPYT
FGGGTKLEIKR
Figure 6. Amino acid sequence differences between murine Mab166 and humanized Fab 1A8. CDR3 in the heavy chain, 
CDR3 and FR4 in the light chain (k) of humanized Fab 1A8 have sequence modifications following humanization and 
affinity maturation compared to corresponding sequences of Mab166.
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5. Conclusion
We have shown in an in vivo study that instillation of a single dose of Fab into the lungs of 
mice protected them against a lethal pulmonary challenge with P. aeruginosa [36]. The ability 
to use a recombinant Fab fragment for the treatment of P. aeruginosa infection in patients with 
ventilator-associated pneumonia or chronically infected cystic fibrosis patients has potential 
to minimize acute lung injury and mortality associated with TTS virulence of P. aeruginosa. 
Further optimization, such as the affinity maturation and PEGylation, will be the next step 
to achieve clinical application in humans. An engineered single-chain antibody that binds to 
the P. aeruginosa PcrV protein with high affinity has strong potential to be an effective new 
therapeutic reagent for infections caused by P. aeruginosa.
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